Base de dados : MEDLINE
Pesquisa : E02.095.147.500.500 [Categoria DeCS]
Referências encontradas : 20705 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2071 ir para página                         

  1 / 20705 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29377903
[Au] Autor:Koldehoff M; Lindemann M; Ross SR; Elmaagacli AH
[Ad] Endereço:Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany.
[Ti] Título:Cytomegalovirus induces HLA-class-II-restricted alloreactivity in an acute myeloid leukemia cell line.
[So] Source:PLoS One;13(1):e0191482, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cytomegalovirus (HCMV) reactivation is found frequently after allogeneic hematopoietic stem cell transplantation (alloSCT) and is associated with an increased treatment-related mortality. Recent reports suggest a link between HCMV and a reduced risk of cancer progression in patients with acute leukemia or lymphoma after alloSCT. Here we show that HCMV can inhibit the proliferation of the acute myeloid leukemia cell line Kasumi-1 and the promyeloid leukemia cell line NB4. HCMV induced a significant up-regulation of HLA-class-II-molecules, especially HLA-DR expression and an increase of apoptosis, granzyme B, perforin and IFN-γ secretion in Kasumi-1 cells cocultured with peripheral blood mononuclear cells (PBMCs). Indolamin-2,3-dioxygenase on the other hand led only to a significant dose-dependent effect on IFN-γ secretion without effects on proliferation. The addition of CpG-rich oligonucleotides and ganciclovir reversed those antiproliferative effects. We conclude that HCMV can enhance alloreactivity of PBMCs against Kasumi-1 and NB4 cells in vitro. To determine if this phenomenon may be clinically relevant further investigations will be required.
[Mh] Termos MeSH primário: Antígenos de Histocompatibilidade Classe II/imunologia
Leucemia Mieloide Aguda/imunologia
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Técnicas de Cocultura
Seres Humanos
Leucemia Mieloide Aguda/terapia
Leucemia Mieloide Aguda/virologia
Transplante de Células-Tronco
Transplante Homólogo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Histocompatibility Antigens Class II)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191482


  2 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28741230
[Au] Autor:Velayudhan L; Ffytche D; Ballard C; Aarsland D
[Ad] Endereço:Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neurosciences, Kings College London, Box PO 70, De Crespigny Park, London, SE5 8AF, UK.
[Ti] Título:New Therapeutic Strategies for Lewy Body Dementias.
[So] Source:Curr Neurol Neurosci Rep;17(9):68, 2017 Sep.
[Is] ISSN:1534-6293
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available symptom treatment strategies are based on monoaminergic, cholinergic and glutaminergic neurotransmitter systems. Relatively robust evidence exists for cholinesterase inhibitors for cognitive impairment in LBD and in Parkinson's disease for antidepressants, clozapine and recently pimavanserin for psychosis. interpidine (RVT 101) and nelotanserin are currently under investigation. Non-pharmacological interventions, such as cognitive stimulation, physical exercises and neuromodulation strategies, may be useful in Parkinson's disease but have not yet been tested in dementias. Disease-modifying approaches are aimed at preventing, slowing or ameliorating the production, aggregation and deposition of pathological proteins, including immunotherapy targeting α-synuclein and an ongoing trial using ambroxol which increases glucocerebrosidase activity to lower the levels of the protein alpha-synuclein. Other disease-modifying clinical trials are using agents to augment insulin signalling, stem cell therapy, reducing amyloid pathology and gene therapy.
[Mh] Termos MeSH primário: Gerenciamento Clínico
Doença por Corpos de Lewy/diagnóstico
Doença por Corpos de Lewy/terapia
[Mh] Termos MeSH secundário: Inibidores da Colinesterase/uso terapêutico
Terapia Genética/tendências
Seres Humanos
Doença por Corpos de Lewy/imunologia
Doença de Parkinson/diagnóstico
Doença de Parkinson/imunologia
Doença de Parkinson/terapia
Piperidinas/uso terapêutico
Transplante de Células-Tronco/tendências
Ureia/análogos & derivados
Ureia/uso terapêutico
alfa-Sinucleína/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Piperidines); 0 (alpha-Synuclein); 8W8T17847W (Urea); JZ963P0DIK (pimavanserin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1007/s11910-017-0778-2


  3 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29317646
[Au] Autor:Rao L; Qian Y; Khodabukus A; Ribar T; Bursac N
[Ad] Endereço:Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
[Ti] Título:Engineering human pluripotent stem cells into a functional skeletal muscle tissue.
[So] Source:Nat Commun;9(1):126, 2018 01 09.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The generation of functional skeletal muscle tissues from human pluripotent stem cells (hPSCs) has not been reported. Here, we derive induced myogenic progenitor cells (iMPCs) via transient overexpression of Pax7 in paraxial mesoderm cells differentiated from hPSCs. In 2D culture, iMPCs readily differentiate into spontaneously contracting multinucleated myotubes and a pool of satellite-like cells endogenously expressing Pax7. Under optimized 3D culture conditions, iMPCs derived from multiple hPSC lines reproducibly form functional skeletal muscle tissues (iSKM bundles) containing aligned multi-nucleated myotubes that exhibit positive force-frequency relationship and robust calcium transients in response to electrical or acetylcholine stimulation. During 1-month culture, the iSKM bundles undergo increased structural and molecular maturation, hypertrophy, and force generation. When implanted into dorsal window chamber or hindlimb muscle in immunocompromised mice, the iSKM bundles survive, progressively vascularize, and maintain functionality. iSKM bundles hold promise as a microphysiological platform for human muscle disease modeling and drug development.
[Mh] Termos MeSH primário: Músculo Esquelético/citologia
Mioblastos/citologia
Células-Tronco Pluripotentes/citologia
Engenharia Tecidual/métodos
[Mh] Termos MeSH secundário: Animais
Diferenciação Celular
Células Cultivadas
Células HEK293
Seres Humanos
Células-Tronco Pluripotentes Induzidas/citologia
Células-Tronco Pluripotentes Induzidas/metabolismo
Camundongos Endogâmicos NOD
Camundongos Knockout
Camundongos Nus
Camundongos SCID
Fibras Musculares Esqueléticas/citologia
Fibras Musculares Esqueléticas/metabolismo
Músculo Esquelético/metabolismo
Mioblastos/metabolismo
Fator de Transcrição PAX7/metabolismo
Células-Tronco Pluripotentes/metabolismo
Transplante de Células-Tronco/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (PAX7 Transcription Factor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02636-4


  4 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457657
[Au] Autor:Sher T; Gertz MA
[Ad] Endereço:Department of Medicine, Mayo Clinic, Jacksonville, Florida. Electronic address: sher.taimur@mayo.edu.
[Ti] Título:Stem cell transplantation for immunoglobulin light chain amyloidosis.
[So] Source:Curr Probl Cancer;41(2):129-137, 2017 Mar - Apr.
[Is] ISSN:1535-6345
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Systemic chemotherapy aimed at eradicating transformed plasma cells is the mainstay of treatment for immunoglobulin light chain amyloidosis (AL). Autologous stem cell transplantation (SCT) is a highly effective treatment for AL and can lead to long term survival in excess of 10 years in patients who achieve complete remission. Since AL is a unique disease characterized by multiple organ dysfunction, SCT poses unique challenges in this disease. Morbidity and mortality of SCT has remarkably improved over time primarily due to careful selection of patients and evolution of predictive and prognostic models based on serum immunoglobulin light chains and cardiac biomarkers. In this review we focus on the historical evolution of SCT as a treatment for AL and unique challenges it poses in the management of this rare disease and provide guidelines for managing these challenges.
[Mh] Termos MeSH primário: Amiloidose de Cadeia Leve de Imunoglobulina/terapia
Transplante de Células-Tronco
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  5 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29381289
[Au] Autor:Ling Q; Wang T; Yu X; Wang SG; Ye ZQ; Liu JH; Yang SW; Zhu XB; Yu J
[Ti] Título:UC-VEGF-SMC Three Dimensional (3D) Nano Scaffolds Exhibits Good Repair Function in Bladder Damage.
[So] Source:J Biomed Nanotechnol;13(3):313-23, 2017 Mar.
[Is] ISSN:1550-7033
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We constructed a UC-VEGF-SMC three dimensional (3D) scaffold to explore its effect on blood vessel regeneration and bladder repair function in a rabbit model with bladder injury. Rabbit adipose tissue-derived stem cells (ADSCs) were cultured to construct pluripotent stem cell systems that can be induced to differentiate into urothelial cells (UCs) and smooth muscle cells (SMCs). Reverse transcriptase-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), immunofluorescence, MTT assay and HE staining were used in our study. Rabbit models were divided into an experimental group, control group and sham group. The bladder histology, urodynamics, smooth muscle function, stent degradation rate, urothelial permeability and biomechanical determination of rabbits were detected after grafting the scaffold. Correct stem cells based on the ADSC surface marker and found that CD90 and CD105 were positive and that CD34 and CD45 were negative. RT-PCR showed that ADSC-iPS cells expressed the marker gene of embryonic stem cells (ESCs), which indicated that Sox2, Klf4, Oct4 and c-Myc were inserted into the iPS nucleus and that the ADSC-iPS system was constructed successfully. Immunofluorescence and MTT assays indicated that iPS differentiated into mature SMCs and UCs. ELISA and HEMC culturing methods revealed that vascular endothelia growth factor (VEGF) could promote the growth of HMECs. Rabbit bladder repair function (urodynamics, smooth muscle function, urothelial permeability and biomechanical determination) was stronger in the experimental group than in the control group. UC-VEGF-SMC 3D nano scaffold exhibits good repair function for bladder damage, which may helpful for treatment of damaged bladders.
[Mh] Termos MeSH primário: Regeneração Tecidual Guiada/instrumentação
Nanoestruturas/química
Transplante de Células-Tronco/instrumentação
Tecidos Suporte
Doenças da Bexiga Urinária/patologia
Doenças da Bexiga Urinária/terapia
Fator A de Crescimento do Endotélio Vascular/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Desenho de Equipamento
Análise de Falha de Equipamento
Feminino
Regeneração Tecidual Guiada/métodos
Masculino
Nanocápsulas/administração & dosagem
Nanocápsulas/química
Nanocápsulas/ultraestrutura
Nanoestruturas/ultraestrutura
Impressão Tridimensional
Coelhos
Recuperação de Função Fisiológica
Transplante de Células-Tronco/métodos
Células-Tronco/citologia
Células-Tronco/fisiologia
Engenharia Tecidual/instrumentação
Engenharia Tecidual/métodos
Resultado do Tratamento
Doenças da Bexiga Urinária/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Nanocapsules); 0 (Vascular Endothelial Growth Factor A)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE


  6 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743464
[Au] Autor:Stonesifer C; Corey S; Ghanekar S; Diamandis Z; Acosta SA; Borlongan CV
[Ad] Endereço:Center of Excellence for Aging and Brain Repair, University of South Florida College of Medicine, 12901 Bruce B Downs Blvd Tampa, FL 33612, USA.
[Ti] Título:Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms.
[So] Source:Prog Neurobiol;158:94-131, 2017 Nov.
[Is] ISSN:1873-5118
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Ischemic stroke is a leading cause of death worldwide. A key secondary cell death mechanism mediating neurological damage following the initial episode of ischemic stroke is the upregulation of endogenous neuroinflammatory processes to levels that destroy hypoxic tissue local to the area of insult, induce apoptosis, and initiate a feedback loop of inflammatory cascades that can expand the region of damage. Stem cell therapy has emerged as an experimental treatment for stroke, and accumulating evidence supports the therapeutic efficacy of stem cells to abrogate stroke-induced inflammation. In this review, we investigate clinically relevant stem cell types, such as hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs), very small embryonic-like stem cells (VSELs), neural stem cells (NSCs), extraembryonic stem cells, adipose tissue-derived stem cells, breast milk-derived stem cells, menstrual blood-derived stem cells, dental tissue-derived stem cells, induced pluripotent stem cells (iPSCs), teratocarcinoma-derived Ntera2/D1 neuron-like cells (NT2N), c-mycER(TAM) modified NSCs (CTX0E03), and notch-transfected mesenchymal stromal cells (SB623), comparing their potential efficacy to sequester stroke-induced neuroinflammation and their feasibility as translational clinical cell sources. To this end, we highlight that MSCs, with a proven track record of safety and efficacy as a transplantable cell for hematologic diseases, stand as an attractive cell type that confers superior anti-inflammatory effects in stroke both in vitro and in vivo. That stem cells can mount a robust anti-inflammatory action against stroke complements the regenerative processes of cell replacement and neurotrophic factor secretion conventionally ascribed to cell-based therapy in neurological disorders.
[Mh] Termos MeSH primário: Morte Celular/fisiologia
Inflamação/terapia
Transplante de Células-Tronco
Acidente Vascular Cerebral/imunologia
Acidente Vascular Cerebral/terapia
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Inflamação/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  7 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457885
[Au] Autor:Brunger JM; Zutshi A; Willard VP; Gersbach CA; Guilak F
[Ad] Endereço:Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
[Ti] Título:Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs.
[So] Source:Stem Cell Reports;8(5):1202-1213, 2017 May 09.
[Is] ISSN:2213-6711
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Chronic inflammatory diseases such as arthritis are characterized by dysregulated responses to pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor α (TNF-α). Pharmacologic anti-cytokine therapies are often effective at diminishing this inflammatory response but have significant side effects and are used at high, constant doses that do not reflect the dynamic nature of disease activity. Using the CRISPR/Cas9 genome-engineering system, we created stem cells that antagonize IL-1- or TNF-α-mediated inflammation in an autoregulated, feedback-controlled manner. Our results show that genome engineering can be used successfully to rewire endogenous cell circuits to allow for prescribed input/output relationships between inflammatory mediators and their antagonists, providing a foundation for cell-based drug delivery or cell-based vaccines via a rapidly responsive, autoregulated system. The customization of intrinsic cellular signaling pathways in stem cells, as demonstrated here, opens innovative possibilities for safer and more effective therapeutic approaches for a wide variety of diseases.
[Mh] Termos MeSH primário: Edição de Genes/métodos
Fatores Imunológicos/genética
Células-Tronco Pluripotentes Induzidas/metabolismo
Transplante de Células-Tronco/métodos
[Mh] Termos MeSH secundário: Animais
Artrite/terapia
Sistemas CRISPR-Cas
Cartilagem/fisiologia
Células Cultivadas
Retroalimentação Fisiológica
Fatores Imunológicos/metabolismo
Células-Tronco Pluripotentes Induzidas/citologia
Células-Tronco Pluripotentes Induzidas/transplante
Interleucina-1/genética
Interleucina-1/metabolismo
Camundongos
Camundongos Endogâmicos C57BL
Regeneração
Fator de Necrose Tumoral alfa/genética
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunologic Factors); 0 (Interleukin-1); 0 (Tumor Necrosis Factor-alpha)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  8 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29395854
[Au] Autor:Sarradin V; Simon L; Huynh A; Gilhodes J; Filleron T; Izar F
[Ad] Endereço:Department of radiotherapy, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France.
[Ti] Título:Total body irradiation using Helical Tomotherapy : Treatment technique, dosimetric results and initial clinical experience.
[So] Source:Cancer Radiother;22(1):17-24, 2018 Feb.
[Is] ISSN:1769-6658
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Helical TomoTherapy allows precise and homogeneous tumour coverage and excellent sparing of organs at risk. We present here our treatment technique, dosimetric results, and our first clinical data for patients receiving total body irradiation as part of the conditioning regimen before hematopoietic stem cell transplantation. PATIENTS AND METHODS: The cohort consisted of 11 patients who were treated in our institution between August 2014 and January 2016. The total dose was 12Gy in six fractions in three days. We collected the dose distribution information in the treatment volumes, organs at risk and area of junction. We report retrospectively the clinical events during the first 6 months after the procedure. RESULTS: Median age was 31 years (range, 18-57 years). Median D98% was 11.5Gy (range: 6.6-11.9Gy). The median of the mean doses to the lungs was 8.7Gy (range: 8.5-9.3Gy). The mean dose for the junction area was 12Gy (range: 11.9-12.1Gy). All patients had the total procedure, and all underwent successful engraftment. During the first six months, nine patients had at least one grade 3 or 4 toxicity that was due essentially to graft versus host disease. No patient had radiation pneumonitis. The toxicities were both more frequent and of higher grade during the first three months. CONCLUSION: Total body irradiation using helical TomoTherapy is feasible. It allows a very good homogeneity of dose and conformity with an acceptable tolerance. It could deliver higher doses to sites at high risk of recurrence (bone marrow, sanctuary sites), while sparing major normal organs like lungs, liver, and kidneys. This reduction of dose could lead to reduced severity and frequency of late complications.
[Mh] Termos MeSH primário: Radioterapia de Intensidade Modulada
Irradiação Corporal Total
[Mh] Termos MeSH secundário: Adolescente
Adulto
Estudos de Coortes
Feminino
Seres Humanos
Leucemia/terapia
Linfoma de Células T/terapia
Masculino
Meia-Idade
Tratamentos com Preservação do Órgão
Órgãos em Risco
Dosagem Radioterapêutica
Radioterapia de Intensidade Modulada/métodos
Estudos Retrospectivos
Transplante de Células-Tronco
Irradiação Corporal Total/métodos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180204
[St] Status:MEDLINE


  9 / 20705 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29172876
[Au] Autor:Yin J; Jurkunas U
[Ad] Endereço:a Massachusetts Eye and Ear, Department of Ophthalmology , Harvard Medical School , Boston , MA , USA.
[Ti] Título:Limbal Stem Cell Transplantation and Complications.
[So] Source:Semin Ophthalmol;33(1):134-141, 2018.
[Is] ISSN:1744-5205
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Corneal epithelial stem cells are adult somatic stem cells located at the limbus and represent the ultimate source of transparent corneal epithelium. When these limbal stem cells become dysfunctional or deficient, limbal stem cell deficiency (LSCD) develops. LSCD is a major cause of corneal scarring and is particularly prevalent in chemical and thermal burns of the ocular surface. LSCD leads to conjunctivalization of the corneal surface, neovascularization, recurrent or persistent epithelial defects, ocular surface inflammation, and scarring that, in turn, lead to decreased vision, pain, and impaired quality of life. Several techniques have been reported for limbal stem cell transplantation (LSCT). We introduce the surgical techniques, examine the success rate, and discuss the postoperative complications of conjunctival limbal autograft (CLAU), cultivated limbal stem cell transplantation (CLET), simple limbal epithelial transplantation (SLET), and limbal allograft, including keratolimbal allografts (KLAL) and living-related conjunctival allograft (LR-CLAL).
[Mh] Termos MeSH primário: Túnica Conjuntiva/transplante
Doenças da Córnea/cirurgia
Transplante de Córnea/métodos
Epitélio Anterior/transplante
Complicações Pós-Operatórias
Transplante de Células-Tronco/métodos
Células-Tronco/citologia
[Mh] Termos MeSH secundário: Túnica Conjuntiva/citologia
Seres Humanos
Transplante Autólogo
Acuidade Visual
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1080/08820538.2017.1353834


  10 / 20705 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28746254
[Au] Autor:Powell MR; Davies BW
[Ad] Endereço:Department of Ophthalmology and Oculofacial Plastic and Reconstructive Surgery, Department of Ophthalmology, San Antonio Uniformed Services Health Education Consortium, San Antonio, Texas, U.S.A.
[Ti] Título:Cicatricial Ectropion Secondary to Graft-Versus-Host Disease.
[So] Source:Ophthal Plast Reconstr Surg;34(1):e22-e23, 2018 Jan/Feb.
[Is] ISSN:1537-2677
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ocular complications of graft-versus-host disease are well documented. While skin changes due to graft-versus-host disease have been mentioned in the literature, cicatricial ectropion has not been previous reported. The authors present a case of a 31-year-old male with cicatricial ectropion secondary to graft-versus-host disease requiring treatment with a full thickness skin graft.
[Mh] Termos MeSH primário: Cicatriz/complicações
Ectrópio/etiologia
Pálpebras/cirurgia
Doença Enxerto-Hospedeiro/complicações
[Mh] Termos MeSH secundário: Adulto
Blefaroplastia
Cicatriz/diagnóstico
Cicatriz/cirurgia
Ectrópio/diagnóstico
Ectrópio/cirurgia
Pálpebras/patologia
Seres Humanos
Masculino
Transplante de Pele/métodos
Transplante de Células-Tronco/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1097/IOP.0000000000000973



página 1 de 2071 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde